Provided by Tiger Trade Technology Pte. Ltd.

Fate Therapeutics

1.14
+0.09008.57%
Post-market: 1.13-0.0069-0.61%19:32 EST
Volume:1.50M
Turnover:1.66M
Market Cap:131.50M
PE:-0.86
High:1.14
Open:1.06
Low:1.05
Close:1.05
52wk High:1.94
52wk Low:0.6611
Shares:115.35M
Float Shares:100.80M
Volume Ratio:0.87
T/O Rate:1.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3180
EPS(LYR):-1.6384
ROE:-52.35%
ROA:-23.85%
PB:0.56
PE(LYR):-0.70

Loading ...

Fate Therapeutics Grants Stock Options and RSUs to New Employee Under Inducement Plan

Reuters
·
Feb 04

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Feb 04

Great week for Fate Therapeutics, Inc. (NASDAQ:FATE) institutional investors after losing 6.3% over the previous year

Simply Wall St.
·
Jan 17

Top Fate Therapeutics Insider Makes a Quiet Move That Investors Can’t Ignore

TIPRANKS
·
Jan 13

Fate Therapeutics Grants Stock Options and RSUs to New Employees

Reuters
·
Jan 06

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jan 06

Fate Therapeutics Reports Promising Phase 1 Results for Off-the-Shelf CAR T-Cell Therapy in Lupus

Reuters
·
Dec 08, 2025

Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference

GlobeNewswire
·
Nov 25, 2025

Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts

TIPRANKS
·
Nov 18, 2025

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP)

TIPRANKS
·
Nov 17, 2025

Navigating Data Privacy Challenges: Fate Therapeutics’ Battle with Regulatory Compliance and Business Risks

TIPRANKS
·
Nov 16, 2025

Fate Therapeutics (FATE) Receives a Hold from Bank of America Securities

TIPRANKS
·
Nov 16, 2025

Analysts Have Conflicting Sentiments on These Healthcare Companies: Indaptus Therapeutics (INDP) and Fate Therapeutics (FATE)

TIPRANKS
·
Nov 14, 2025

Fate Therapeutics: Balancing Potential and Uncertainty with FT819’s Promise in Autoimmune Treatment

TIPRANKS
·
Nov 13, 2025

Fate Therapeutics Q3 EPS $(0.27) Beats $(0.29) Estimate, Sales $1.741M Beat $1.535M Estimate

Benzinga
·
Nov 13, 2025

Fate Therapeutics reports Q3 EPS (27c), consensus (28c)

TIPRANKS
·
Nov 13, 2025

Fate Therapeutics reports third quarter 2025 revenue of $1.7 million

Reuters
·
Nov 13, 2025

Fate Therapeutics Q3 Net Income USD -32.25 Million

THOMSON REUTERS
·
Nov 13, 2025

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

GlobeNewswire
·
Nov 13, 2025

Fate Therapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview

Reuters
·
Nov 07, 2025